Veno-venous extracorporeal membrane oxygenation (vv-ECMO) is pivotal in the treatment of patients suffering from acute respiratory distress syndrome (ARDS). Comparative data with different oxygenator models have not yet been reported. The aim of this retrospective investigation was therefore to assess whether different oxygenator types might influence changing frequency, infection incidence, and mortality in patients on vv-ECMO.
Methods
42 patients undergoing vv-ECMO between 1998 and 2009 were identified. In 20 out of these patients, a polypropylene (PP) microporous hollow fiber membrane oxygenator, and in 22 patients a nonmicroporous polymethylpentene (PMP) diffusion membrane oxygenator was used. Infection incidence, changing frequency, and mortality were documented.
Results
In the PMP group, an oxygenator change was necessary less often than in the PP group (p<0.001). The incidence of bacterial, viral, or fungal growth was similar in the groups, thus independent of the frequency of oxygenator change. Irrespective of the groups, the occurrence of Candida sp. tended to correlate with death (p = 0.06). In general, there was a trend towards a higher infection incidence in the subgroup with pulmonary ARDS (p = 0.07). Moreover, infection incidence was associated with a longer ICU stay (p = 0.03) and longer ECMO therapy (p = 0.03). ICU mortality was lower in the PMP group than in the PP group, although not statistically significant (p = 0.10).
Conclusions
The PMP oxygenator membranes showed benefits with regards to changing frequency, but not infection incidence, length of ICU stay, and length of ECMO therapy. There was a trend towards a lower ICU mortality in patients with PMP oxygenators.
LewandowskiK.Extracorporeal membrane oxygenation for severe acute respiratory failure. Crit Care.2000; 4(3): 156–168.
2.
HirshbergE., MillerR.R.III, MorrisA.H.Extracorporeal membrane oxygenation in adults with acute respiratory distress syndrome. Curr Opin Crit Care.2013; 19(1): 38–43.
3.
HodgsonC.L., HayesK., EverardT.Long-term quality of life in patients with acute respiratory distress syndrome requiring extracorporeal membrane oxygenation for refractory hypoxaemia. Crit Care.2012; 16(5): R202.
4.
PeekG.J., MugfordM., TiruvoipatiR.; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet.2009; 374(9698): 1351–1363.
5.
DaviesA., JonesD., BaileyM.; Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA.2009; 302(17): 1888–1895.
6.
BeurtheretS., MastroianniC., PozziM.Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome: single-centre experience with 1-year follow-up. Eur J Cardiothorac Surg.2012; 41(3): 691–695.
7.
SchellongowskiP., UllrichR., HieberC.A surge of fluassociated adult respiratory distress syndrome in an Austrian tertiary care hospital during the 2009/2010 Influenza A H1N1v pandemic. Wien Klin Wochenschr.2011; 123(7-8): 209–214.
8.
NoahM.A., PeekG.J., FinneyS.J.Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA.2011; 306(15): 1659–1668.
9.
ZapolW.M., SniderM.T., HillJ.D.Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA.1979; 242(20): 2193–2196.
10.
PappalardoF., PieriM., GrecoT.; Italian ECMOnet. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med.2013; 39(2): 275–281.
11.
PhuaJ., BadiaJ.R., AdhikariN.K.Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med.2009; 179(3): 220–227.
KredelM., BischofL., WurmbT., RoewerN., MuellenbachR.Combination of positioning therapy and venovenous extracorporeal membrane oxygenation in ARDS patients. Perfusion.2014; 29(2): 171–177.
14.
Serpa NetoA., CardosoS.O., ManettaJ.A.Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA.2012; 308(16): 1651–1659.
15.
GalvinI.M., SteelA., PintoR., FergusonN.D., DaviesM.W.Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev.2013; 7: CD003707.
YuK., LongC., HeiF.Clinical evaluation of two different extracorporeal membrane oxygenation systems: a single center report. Artif Organs.2011; 35(7): 733–737.
18.
MeyerA.D., WilesA.A., RiveraO.Hemolytic and thrombocytopathic characteristics of extracorporeal membrane oxygenation systems at simulated flow rate for neonates. Pediatr Crit Care Med.2012; 13(4): e255–e261.
19.
BurnsideJ., GomezD., PrestonT.J., OlshoveV.F.Jr., PhillipsA.In-vitro quantification of gaseous microemboli in two extracorporeal life support circuits. J Extra Corpor Technol.2011; 43(3): 123–129.
20.
LimM.W.The history of extracorporeal oxygenators. Anaesthesia.2006; 61(10): 984–995.
21.
FormicaF., AvalliL., MartinoA.Extracorporeal membrane oxygenation with a poly-methylpentene oxygenator (Quadrox D). The experience of a single Italian centre in adult patients with refractory cardiogenic shock. ASAIO J.2008; 54(1): 89–94.
22.
TayamaE., HayashidaN., AkasuK.Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs.2000; 24(8): 618–623.
23.
BartlettR.H.Extracorporeal life support: history and new directions. ASAIO J.2005; 51(5): 487–489.
24.
TanakaM., KawahitoK., AdachiH., IsawaH., InoT.Platelet damage caused by the centrifugal pump: laser-light scattering analysis of aggregation patterns. Artif Organs.2001; 25(9): 719–723.
SunH.Y., KoW.J., TsaiP.R.Infections occurring during extracorporeal membrane oxygenation use in adult patients. J Thorac Cardiovasc Surg. Nov2010; 140(5): 1125–1132.e2. PubMed
27.
MagovernG.J.Jr., MagovernJ.A., BenckartD.H.Extracorporeal membrane oxygenation: preliminary results in patients with postcardiotomy cardiogenic shock. Ann Thorac Surg.1994; 57(6): 1462–1470.
28.
AubronC., ChengA.C., PilcherD.Infections acquired by adults who receive extracorporeal membrane oxygenation: risk factors and outcome. Infect Control Hosp Epidemiol.2013; 34(1): 24–30.
29.
DouglassB.H., KeenanA.L., PurohitD.M.Bacterial and fungal infection in neonates undergoing venoarterial extracorporeal membrane oxygenation: an analysis of the registry data of the extracorporeal life support organization. Artif Organs.1996; 20(3): 202–208.
30.
SchutzeG.E., HeulittM.J.Infections during extracorporeal life support. J Pediatr Surg.1995; 30(6): 809–812.
31.
BernardG.R., ArtigasA., BrighamK.L.The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med.1994; 149(3): 818–824.
32.
RanieriV.M., RubenfeldG.D., ThompsonB.T.; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA.2012; 307(23): 2526–2533.
33.
UllrichR., LorberC., RöderG.Controlled airway pressure therapy, nitric oxide inhalation, prone position, and extracorporeal membrane oxygenation (ECMO) as components of an integrated approach to ARDS. Anesthesiology.1999; 91(6): 1577–1586.
34.
IwahashiH., YuriK., NoséY.Development of the oxygenator: past, present, and future. J Artif Organs.2004; 7(3): 111–120.
35.
HortonS., ThuysC., BennettM., AugustinS., RosenbergM., BrizardC.Experience with the Jostra Rotaflow and QuadroxD oxygenator for ECMO. Perfusion.2004; 19(1): 17–23.
36.
PluimT., HalasaN., PhillipsS.E., FlemingG.The morbidity and mortality of patients with fungal infections before and during extracorporeal membrane oxygenation support. Pediatr Crit Care Med.2012; 13(5): e288–e293.
37.
GarciaX., MianA., MendirattaP., GuptaP., RycusP., ProdhanP.Aspergillus infection and extracorporeal membrane oxygenation support. J Intensive Care Med.2013; 28(3): 178–184.
38.
KuehnC., OrszagP., BurgwitzK.Microbial adhesion on membrane oxygenators in patients requiring extracorporeal life support detected by a universal rDNA PCR test. ASAIO J.2013; 59(4): 368–373.
39.
AmarelliC., MastroianniC., BrechotN.Prompt diagnosis of a new clinical entity: membrane oxygenator infection during ECMO. ASAIO J.2013; 59(4): 367.
40.
HsuM.S., ChiuK.M., HuangY.T., KaoK.L., ChuS.H., LiaoC.H.Risk factors for nosocomial infection during extracorporeal membrane oxygenation. J Hosp Infect.2009; 73(3): 210–216.
